WearOptimo
WearOptimo is an Australian health-technology company developing Microwearable sensors with hair-width micro-electrodes and AI to continuously monitor hydration biomarkers, serving elite sports, mining, defense and aged care markets with commercial launch targeted for 2026.
- Company typePrivate
- Founded2018
- HeadquartersBrisbane, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What WearOptimo does
WearOptimo Pty Ltd is an Australian health-technology company founded in 2018 by Professor Mark Kendall as the Australian National University's first partner innovation company, headquartered in Brisbane, Queensland. The company develops Microwearable sensors that use hair-width micro-electrodes to painlessly penetrate the outer skin layer and access biomarkers in interstitial fluid, combined with AI/machine learning analytics designed to generalize across users without per-individual recalibration. Its first commercial product is a Hydration Microwearable Sensor targeting elite sports, mining, defense and aged care markets, with a Cardiac Microwearable Sensor in development and longer-term aspirations in sepsis and cardiovascular early detection. Technology is protected by 15 granted patents across 9 patent families with 45 total filings spanning Australia, the US, Europe, Japan, Canada and China. WearOptimo has built an Advanced Manufacturing Facility in Queensland using Nanoimprint Lithography, the first such facility in the southern hemisphere dedicated to health-tech, with stated capacity of up to 30 million sensors annually at full operation.
The business model combines hardware sales of the sensor devices with a recurring subscription component from its companion Smart App Analytics application, sold primarily through enterprise B2B channels. Aspen Medical serves as the cornerstone strategic distribution partner for mining, defense and aged care markets, while elite sports is targeted through direct enterprise sales and high-profile individual partnerships such as F1 champion Mark Webber AO. The company is pre-commercial, having commenced pilot clinical trials at QUT in 2023 and presenting clinical validation data at LSI USA '25 in March 2025 showing the hydration sensor outperforming needle-based serum osmolality gold standard. Funding has come from a mix of Australian federal and Queensland government grants, strategic corporate investment from Aspen Medical, and individual investors including Mark Webber AO and Adam MacDougall, with cumulative capital exceeding $50M and an ongoing $10M raise to fund commercial readiness for a targeted 2026 launch.
WearOptimo firmographics
Firmographics- Name
- WearOptimo
- Legal name
- WearOptimo Pty Ltd
- Website
- https://wearoptimo.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- WearOptimo is an Australian health-technology company developing Microwearable sensors with hair-width micro-electrodes and AI to continuously monitor hydration biomarkers, serving elite sports, mining, defense and aged care markets with commercial launch targeted for 2026.
- Ownership category
- akta.pro rank
WearOptimo industry classification
Industry- Product category
- Wearable Medical Biosensors
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), Other Measuring and Controlling Device Manufacturing (334519)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)
- akta.pro secondary industries
- Consumer Health Wearables & Fitness Trackers (Wellness Monitoring) (HLAHACAJ), Health Monitoring Wearables (ECG, BP, SpO2, CGM-compatible) (CRACAIAF), Hydration, Nutrition & Metabolic Tracking Devices (Smart Bottles, Breath/Metabolic Analyzers) (CRACAQAI)
Keywords
Where WearOptimo is headquartered
LocationHeadquarters
- HQ city
- Brisbane
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
WearOptimo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain
Revenue model
- Hydration Microwearable Sensors: Sale of wearable hydration monitoring sensors as the first product to market. The sensors are pain-free, sticker-like devices that provide continuous real-time hydration monitoring.
- Smart App Analytics Subscription: Ongoing subscription for smartphone app analytics providing hydration metrics, insights and alerts
- Enterprise/B2B Sensor Contracts: Bulk sensor supply agreements with enterprise clients in mining, defense, aged care, and sports sectors
Go-to-market motion2 records
Distribution channels3 records
Marketing channels13 records
WearOptimo product offering
Product offeringCore offering
WearOptimo develops and manufactures Microwearable sensors — pain-free, sticker-like devices with hair-width microneedle electrodes that penetrate the outer skin layer to access biomarkers in interstitial fluid for continuous, real-time health monitoring. Its first commercial product is the Hydration Microwearable Sensor, paired with AI-driven Smart App Analytics that delivers hydration metrics, insights and alerts to a smartphone app. The underlying platform is intended to extend to cardiac and other biomarker monitoring applications.
Product overview
WearOptimo offers a portfolio of Microwearable health monitoring products built on a proprietary technology platform. The core product is the Hydration Microwearable Sensor, a pain-free continuous monitoring device that uses microscopic electrodes penetrating just the outer skin layer to measure hydration biomarkers in real time. This primary product is supported by a companion Smart App Analytics module providing AI-driven insights and alerts. The underlying Microwearable Technology Platform is designed to be extensible, supporting additional biomarker monitoring applications including Cardiac Microwearable Sensors for early detection of cardiovascular events. The platform leverages advanced manufacturing using Nanoimprint Lithography (NIL) to produce sensors at scale.
Differentiator
Problem solved
Functional benefit
Products and services
- Hydration Microwearable Sensor Pain-free, sticker-like wearable device with hair-width microneedle electrodes that penetrate just the outer skin layer (epidermis) to access biomarkers in interstitial fluid and deliver continuous, real-time hydration monitoring. Designed for enterprise customers in elite sports, mining, defense, aged care, and construction, with clinical accuracy demonstrated to outperform needle-based gold standard blood tests.
- Microwearable Technology Platform Patent-protected platform technology using microscopic electrodes that painlessly penetrate the outer skin layer to access biomarkers in real time. The platform enables continuous monitoring for hydration and is being extended to early detection of cardiovascular events, sepsis, and other health conditions, serving as the underlying basis for WearOptimo's product portfolio.
- Cardiac Microwearable Sensor Sensor under development designed for early detection of heart attacks and cardiovascular disease through continuous monitoring of cardiac biomarkers via the Microwearable technology platform. Targeted at clinical and consumer health monitoring applications.
Quantifiable outcome
- WearOptimo's hydration sensor demonstrated significantly greater accuracy (sensitivity and selectivity) at detecting mild dehydration compared to serum osmolality gold standard achieved via blood draws
- +5 more outcomes
Companies that use WearOptimo
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles5 records
WearOptimo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
WearOptimo partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor and core.
- World Health OrganizationminorMentioned as one of the organizations that has drawn attention to founder Mark Kendall's inventions
- Bill & Melinda Gates FoundationminorMentioned as organization that has drawn attention to founder Mark Kendall's prior work in vaccine technology
- Advisory Board MemberscoreWorld-class advisory board including Dr. Robert Langer (MIT, co-founded Moderna), Dr. Douglas Williams (former Biogen EVP R&D), Peter Barton Hutt (former FDA Chief Counsel), Dr. Luke Bennett (former F1 performance director), Jeff Wong (former EY Global Chief Innovation Officer), and Dr. Peter Wrighton-Smith (Oxford Immunotec founder). Advisory board provides strategic insights and industry network access for global scaling.
- Australian National Fabrication Facility (ANFF)coreANFF provides advanced fabrication capabilities supporting WearOptimo's manufacturing scale-up. The long-standing collaboration has created novel microstructures on research scale and supports transition to production phase.
- Aspen MedicalcoreGlobal healthcare provider Aspen Medical serves as key distribution partner for WearOptimo's hydration microwearable sensors in mining, resource, defense, and aged care sectors. The partnership includes development, field trials, refinement, commercialization, and distribution. Aspen Medical founder Glenn Keys AO joined WearOptimo's board. The partnership provides access to key markets across industries such as military and mining.
- Australian National University (ANU)coreANU is WearOptimo's foundational innovation partner. The company was founded as ANU's first partner innovation company. ANU provides strategic and investment support, including dollar-matching funding for grants. The partnership enables access to research capabilities and the university's innovation ecosystem.
Scale indicators11 records
Recent moves9 records
Expansion highlights6 records
WearOptimo competitors and assessment
Company assessmentBroad incumbents
- Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the global market-leading continuous biosensor (CGM), demonstrating the commercial viability of wearable biomarker monitoring at massive scale. WearOptimo's interstitial-fluid microneedle approach is directly comparable as an adjacent biosensing platform targeting hydration and other biomarkers.
- Dexcom: Dexcom is the leading continuous glucose monitor company, validating the wearable biosensor business model in clinical and consumer markets. Comparable to WearOptimo in offering continuous biomarker monitoring via a wearable patch, with substantially greater scale and a more mature commercial footprint.
- Masimo: Masimo manufactures patient monitoring devices and biosensing technologies used in hospitals and clinical settings. Comparable to WearOptimo as a medical-grade sensor and monitoring company with continuous physiological parameter measurement capabilities.
- Medtronic: Medtronic produces a broad portfolio of implantable and wearable medical devices, including continuous monitoring sensors. Comparable to WearOptimo as a diversified medical device manufacturer with continuous biomarker monitoring capabilities and global regulatory infrastructure.
- Whoop: Whoop is a subscription wearable providing continuous physiological monitoring for athletes, including strain, sleep, and recovery. Comparable to WearOptimo in targeting elite sports and offering continuous biometric monitoring, though Whoop focuses on optical/skin-surface metrics whereas WearOptimo accesses interstitial fluid via microneedles.
- Oura: Oura produces a smart ring for continuous health tracking, including sleep, recovery, and readiness metrics. Comparable to WearOptimo as a consumer-grade continuous health monitoring wearable, though Oura uses ring-based optical sensors while WearOptimo's microneedle patch accesses interstitial fluid biomarkers.
Direct peers
- BioIntellisense: BioIntellisense provides continuous multi-parameter wearable monitoring through a disposable biosensor patch for clinical and remote patient monitoring use cases. Highly comparable to WearOptimo's hydration sensor as a direct competitor in continuous wearable biomarker monitoring for enterprise and healthcare markets.
- iRhythm Technologies: iRhythm's Zio cardiac monitor is a wearable patch that continuously monitors cardiac biomarkers outside the clinic. Comparable to WearOptimo as a wearable biosensor for continuous biomarker monitoring with clinical-grade evidence and FDA-cleared applications, particularly relevant given WearOptimo's cardiac microwearable roadmap.
Emerging players
- Vaxxas: Vaxxas, founded by WearOptimo's founder Professor Mark Kendall, commercializes the Nanopatch vaccine delivery platform using similar microneedle technology. Directly comparable as a sister company commercializing microneedle-based biomedical technology and validating the underlying science that WearOptimo builds on.
- LifeSignals: LifeSignals develops disposable wearable biosensor patches for continuous patient monitoring of multiple physiological parameters. Comparable to WearOptimo as a direct emerging competitor in continuous wearable biosensors for remote monitoring applications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
WearOptimo social profiles
Digital presenceWearOptimo financial estimates
Financial estimateRevenue estimate
Valuation estimate
WearOptimo leadership team
Management profileNumber of profiles
Profiles5 records
WearOptimo funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WearOptimo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WearOptimo
What does WearOptimo do?
WearOptimo develops and manufactures Microwearable sensors — pain-free, sticker-like devices with hair-width microneedle electrodes that penetrate the outer skin layer to access biomarkers in interstitial fluid for continuous, real-time health monitoring. Its first commercial product is the Hydration Microwearable Sensor, paired with AI-driven Smart App Analytics that delivers hydration metrics, insights and alerts to a smartphone app. The underlying platform is intended to extend to cardiac and other biomarker monitoring applications.
Is WearOptimo a public or private company?
WearOptimo is a private company. It is classified as venture growth investor backed and is currently operating.
When was WearOptimo founded?
WearOptimo was founded in 2018. It employs 11 to 50 people.
Where is WearOptimo based?
WearOptimo is headquartered in Brisbane, Australia, in the Oceania region.
How does WearOptimo make money?
Three revenue lines are on record. Hydration Microwearable Sensors are the primary driver. The others are smart App Analytics Subscription and enterprise/B2B Sensor Contracts.
Who are WearOptimo's main competitors?
Broad incumbents on record are Abbott (FreeStyle Libre), Dexcom, Masimo, Medtronic, Whoop and Oura. Direct peers are BioIntellisense and iRhythm Technologies. Emerging players are Vaxxas and LifeSignals.
Does WearOptimo have an API?
No public API is recorded for WearOptimo.
What industry is WearOptimo in?
WearOptimo's product category is Wearable Medical Biosensors. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLAHACAJ, Consumer Health Wearables & Fitness Trackers (Wellness Monitoring). Its NAICS code is 334510 and its SIC code is 3841.